Literature DB >> 36059381

Contrast-enhanced MR Angiography without Gadolinium-based Contrast Material: Clinical Applications Using Ferumoxytol.

Mohammad H Jalili1, Tiffany Yu1, Cameron Hassani1, Ashley E Prosper1, J Paul Finn1, Arash Bedayat1.   

Abstract

Vascular imaging can be challenging because of the wide variability of contrast dynamics in different vascular territories and potential safety concerns in patients with renal insufficiency or allergies. Off-label diagnostic use of ferumoxytol, a superparamagnetic iron nanoparticle approved for therapy, is a promising alternative to gadolinium-based contrast agents for MR angiography (MRA). Ferumoxytol has exhibited a reassuring safety profile when used within the dose range recommended for diagnostic imaging. Because of its prolonged and stable intravascular residence, ferumoxytol can be used in its steady-state distribution for a wide variety of imaging indications, including some where conventional MRA is unreliable. In this article, authors discuss some of the major vascular applications of ferumoxytol and highlight how it may be used to provide highly diagnostic images and improve the quality, workflow, and reliability of vascular imaging. Keywords: MR Angiography, MRI Contrast Agent, Cardiac, Vascular © RSNA, 2022.
© 2022 by the Radiological Society of North America, Inc.

Entities:  

Keywords:  Cardiac; MR Angiography; MRI Contrast Agent; Vascular

Year:  2022        PMID: 36059381      PMCID: PMC9434982          DOI: 10.1148/ryct.210323

Source DB:  PubMed          Journal:  Radiol Cardiothorac Imaging        ISSN: 2638-6135


  57 in total

1.  First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent.

Authors:  Wei Li; Sean Tutton; Anthony T Vu; Linda Pierchala; Belinda S Y Li; Jerome M Lewis; Pottumarthi V Prasad; Robert R Edelman
Journal:  J Magn Reson Imaging       Date:  2005-01       Impact factor: 4.813

Review 2.  Noncontrast MR angiography: An update.

Authors:  Robert R Edelman; Ioannis Koktzoglou
Journal:  J Magn Reson Imaging       Date:  2018-12-19       Impact factor: 4.813

3.  Intravenous Ferumoxytol in Pediatric Patients With Iron Deficiency Anemia.

Authors:  Nabil Hassan; Brian Boville; Diann Reischmann; Akunne Ndika; David Sterken; Karen Kovey
Journal:  Ann Pharmacother       Date:  2017-03-13       Impact factor: 3.154

Review 4.  Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.

Authors:  Dragan Stojanov; Aleksandra Aracki-Trenkic; Daniela Benedeto-Stojanov
Journal:  Neuroradiology       Date:  2016-02-12       Impact factor: 2.804

5.  CT evaluation of unrepaired/incidental congenital cardiovascular diseases in adults.

Authors:  Arash Bedayat; Mohammad H Jalili; Cameron Hassani; Hamid Chalian; Stefan Reuhm; John Moriarty
Journal:  Diagn Interv Imaging       Date:  2020-10-21       Impact factor: 4.026

6.  Acute cardiac transplant rejection: detection and grading with MR imaging with a blood pool contrast agent--experimental study in the rat.

Authors:  Lars Johansson; Cecilia Johnsson; Eva Penno; Atle Björnerud; Håkan Ahlström
Journal:  Radiology       Date:  2002-10       Impact factor: 11.105

7.  Four-dimensional, multiphase, steady-state imaging with contrast enhancement (MUSIC) in the heart: a feasibility study in children.

Authors:  Fei Han; Stanislas Rapacchi; Sarah Khan; Ihab Ayad; Isidro Salusky; Simon Gabriel; Adam Plotnik; J Paul Finn; Peng Hu
Journal:  Magn Reson Med       Date:  2014-10-09       Impact factor: 4.668

8.  Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases.

Authors:  Mustafa R Bashir; Rekha Mody; Amy Neville; Ramin Javan; Danielle Seaman; Charles Y Kim; Rajan T Gupta; Tracy A Jaffe
Journal:  J Magn Reson Imaging       Date:  2013-10-15       Impact factor: 4.813

Review 9.  Cardiovascular MRI with ferumoxytol.

Authors:  J P Finn; K-L Nguyen; F Han; Z Zhou; I Salusky; I Ayad; P Hu
Journal:  Clin Radiol       Date:  2016-05-21       Impact factor: 3.389

10.  Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI.

Authors:  Anne Monika Muehe; Florian Siedek; Ashok Joseph Theruvath; Jayne Seekins; Sheri L Spunt; Allison Pribnow; Florette Kimberly Hazard; Tie Liang; Heike Daldrup-Link
Journal:  Theranostics       Date:  2020-02-18       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.